Skip to main content
Premium Trial:

Request an Annual Quote

Not a Favored Move

Jeremy Farrar, the director of the Wellcome Trust, has criticized the move to replace Public Health England, the Guardian reports.

Earlier this week, the Telegraph reported that UK Health Secretary Matt Hancock plans to eliminate the agency and replace it with one called the National Institute for Health Protection that is to also encompass the National Health Service's Test and Trace program. The change comes as ministers have been displeased with how PHE has handled the COVID-19 pandemic.

According to the Guardian, Farrar, who is also a member of the Scientific Advisory Group on Emergencies, says the decision represents a "passing of blame" and is "ill thought through." He adds that "kneejerk, reactive, short-term reforms that fail to listen or learn lessons from past, present crisis and future trends will be [a] wasted opportunity for needed reform, public health, social services, and medical care."

Hancock says he is typically not in favor of large reorganizations, but argues this one is necessary, according to the Guardian. "But I think this one is absolutely the best thing to do and the best thing to do right now because we need to bring together the different parts of the response [to coronavirus]," he adds.

The Scan

RNA Editing in Octopuses Seems to Help Acclimation to Shifts in Water Temperature

A paper in Cell reports that octopuses use RNA editing to help them adjust to different water temperatures.

Topical Compound to Block EGFR Inhibitors May Ease Skin Toxicities, Study Finds

A topical treatment described in Science Translational Medicine may limit skin toxicities seen with EGFR inhibitor therapy.

Dozen Genetic Loci Linked to Preeclampsia Risk in New GWAS

An analysis of genome-wide association study data in JAMA Cardiology finds genetic loci linked to preeclampsia that have ties to blood pressure.

Cancer Survival Linked to Mutational Burden in Pan-Cancer Analysis

A pan-cancer paper appearing in JCO Precision Oncology suggests tumor mutation patterns provide clues for predicting cancer survival that are independent of other prognostic factors.